UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
Stock analysis
UnitedHealth Group IncorporatedUNH UnitedHealth Group Incorporated fair value $340–$450
Affichage de la source anglaise pendant la traduction
Ce rapport n'a pas encore été traduit. Actualisez dans quelques minutes une fois que la file d'attente de traduction aura rattrapé son retard.
§1 Résumé
UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$378.07Price
FV $339.99
High $449.63
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.
Cycle upside
Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.
Based on our latest analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Our composite fair-value range for UNH is $230–$450, with a midpoint of $340. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for UnitedHealth Group Incorporated's archetype.
Our current rating for UNH is Reduce with a confidence score of 88/100. We rate UNH a Reduce (or Hold for strictly long-term, tax-sensitive accounts). The heavily penalized $339.99 midpoint reflects near-term operational realities. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for UnitedHealth Group Incorporated are: Permanent MA Rate Cuts; Runaway Medical Inflation; Antitrust Optum Breakup. The single biggest risk is Permanent MA Rate Cuts: Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.
Our current rating for UNH is Reduce, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($230–$450) versus the current price of $378.
UnitedHealth Group Incorporated is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for UNH.
